Vanguard Capital Management
APUS

Vanguard Capital Management’s Apimeds Pharmaceuticals US APUS Stock Holding History

Vanguard Capital Management’s Portfolio APUS Stock Details APUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$57.3K Sell
6,365
-3,228
-34% -$44K ﹤0.01% 3926
2026
Q1 		$172K Buy
+9,593
New +$154K ﹤0.01% 3816

Other funds holding APUS

HTHT
Hemenway Trust Hemenway Trust Salem, New Hampshire $1.43B AUM 37.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Vanguard Capital Management's APUS Position: Q2 2026 in Review

Vanguard Capital Management reduced its Apimeds Pharmaceuticals US (APUS) stake by 34% in Q2 2026, selling an estimated $44K and leaving 6,365 shares worth $57.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3926.

Vanguard Capital Management first reported a position in APUS in Q1 2026 and has held it in 2 quarters since. The position peaked at $172K in Q1 2026. 7 funds tracked by Wall St. Rank hold APUS as of Q2 2026.

  • Vanguard Capital Management held 6,365 shares of Apimeds Pharmaceuticals US worth $57.3K as of Q2 2026.
  • Vanguard Capital Management sold 3,228 Apimeds Pharmaceuticals US shares in Q2 2026, an estimated $44K.
  • Apimeds Pharmaceuticals US made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3926 holding.
  • Vanguard Capital Management first reported a position in Apimeds Pharmaceuticals US in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Apimeds Pharmaceuticals US position peaked at $172K in Q1 2026.
  • 7 funds tracked by Wall St. Rank held Apimeds Pharmaceuticals US as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.